Efficacy and Safety of Prolonged Use of Eltrombopag and Romiplostim in Routine Clinical Practice in Patients with Chronic ITP.

Next Previous
Trial Profile

Efficacy and Safety of Prolonged Use of Eltrombopag and Romiplostim in Routine Clinical Practice in Patients with Chronic ITP.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2016

At a glance

  • Drugs Eltrombopag (Primary) ; Romiplostim (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 06 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top